| Issue | Title | |
| Vol 2022, No 6 (2022) | Biogen Licenses Parkinson’s Drug from Alectos Therapeutics for up to US$722.5 M | Abstract pdf html |
| Ashish Tripathi | ||
| Vol 2020, No 12 (2020) | Biogen Licenses Sage’s GABAA Modulators to Bolster CNS Pipeline | Abstract pdf html |
| Pratika Pahwa & Michelle Liu | ||
| Vol 2017, No 12 (2017) | Biogen Looks to Extend its MS Leadership Through Licensing | Abstract pdf html |
| Jasmine Kalsi | ||
| Vol 2021, No 6 (2021) | Biogen Partners with Capsigen on AAV Capsids | Abstract pdf html |
| Michelle Liu | ||
| Vol 2016, No 6 (2016) | Biogen Revamps its Outlook by Licensing Next Generation Gene Therapies | Abstract pdf html |
| Jasmine Kalsi | ||
| Vol 2020, No 3 (2020) | Biogen Signs Preclinical Gene Editing Deal with Sangamo | Abstract html pdf |
| Michelle Liu | ||
| Vol 2017, No 6 (2017) | Biogen Spin-Off Bioverativ to Acquire True North Therapeutics for up to US$825 M | Abstract html pdf |
| Natasha Piper | ||
| Vol 2024, No 5 (2024) | Biogen to Acquire Immunology Drugmaker HI-Bio for US$1.8 B | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2023, No 8 (2023) | Biogen to Acquire Reata for US$7.3 B for Rare Disease Portfolio | Abstract pdf html |
| Lalit Mishra | ||
| Vol 2005, No 60 (2005) | BioGeneriX to Develop Second Protein Using Neose’s GlycoPEGylation(TM) Technology | Abstract pdf |
| Business Review Editor | ||
| Vol 2015, No 10 (2015) | BioMarin Exits Oncology Sector by Selling Talazoparib to Medivation in US$570 M Deal | Abstract html |
| Heather Cartwright & Sayani Datta | ||
| Vol 2008, No 98 (2008) | BioMarin Licenses Summit’s Muscular Dystrophy Programme | Abstract pdf html |
| Taskin Ahmed | ||
| Vol 2010, No 2 (2010) | BioMarin's Foray into Oncology with Lead Therapeutics Acquisition | Abstract |
| Taskin Ahmed | ||
| Vol 2020, No 1 (2020) | BioNTech Acquires Struggling Neon for US$67 M | Abstract html pdf |
| Michelle Liu | ||
| Vol 2018, No 8 (2018) | BioNTech and Pfizer Join the mRNA Space in US$425 M Deal | Abstract pdf html |
| Michelle Liu | ||
| Vol 2023, No 3 (2023) | BioNTech Collaborates with OncoC4 to Co-Develop CTLA-4 Cancer Antibody | Abstract pdf html |
| Ayush Saxena | ||
| Vol 2023, No 4 (2023) | BioNTech Enters ADC Field with US$1.6 B+ DualityBio Licensing Deal | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2020, No 4 (2020) | Biopharma Companies Join Forces to Fight COVID-19 | Abstract pdf html |
| Heather Cartwright & Taskin Ahmed | ||
| Vol 2006, No 75 (2006) | Biopharmaceutical Clusters in Europe: Differences and Similarities | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 38 (2003) | BioSilicon™: A Nanotechnology Deal Platform | Abstract |
| Business Review Editor | ||
| Vol 2009, No 3 (2009) | Biosimilars – a risky bet? | Abstract |
| Taskin Ahmed | ||
| Vol 2009, No 11 (2009) | Biota Accelerates Anti-infective Portfolio | Abstract |
| Taskin Ahmed | ||
| Vol 2006, No 69 (2006) | Biotech acquisition | Details jpg |
| Business Review Editor | ||
| Vol 2005, No 62 (2005) | Biotechnology Means Hope | Details html |
| Fintan Walton | ||
| Vol 2007, No 88 (2007) | Biotest makes Move for US Market | Abstract pdf |
| Business Review Editor | ||
| Vol 2011, No 10 (2011) | Biotie Agrees to Acquire Newron to Strengthen its Late-Stage CNS Pipeline | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 1 (2011) | Biotie Therapies Expands CNS Pipeline with Acquisition of Synosia Therapeutics | Abstract |
| Heather Cartwright | ||
| Vol 2002, No 25 (2002) | Biovail acquires Vasotec®/Vaseretic® from Merck & Co. | Abstract pdf |
| Business Review Editor | ||
| Vol 2010, No 2 (2010) | Biovail and Alexza to Develop Inhaled Antipsychotic | Abstract |
| Taskin Ahmed | ||
| Vol 2010, No 7 (2010) | Biovail Takes Over Valeant via Reverse Merger to Expand Business Model | Abstract |
| Heather Cartwright | ||
| Vol 2002, No 31 (2002) | BioXell SpA | Abstract pdf |
| Business Review Editor | ||
| Vol 2011, No 11 (2011) | Birthday | Abstract jpg |
| Clive Goddard | ||
| Vol 2019, No 1 (2019) | BMS Acquires Celgene in First Major Deal of 2019 | Abstract pdf |
| Michelle Liu & Jawala Prasad | ||
| Vol 2016, No 7 (2016) | BMS Acquires Cormorant to Expand Immuno-oncology Pipeline | Abstract pdf html |
| Jasmine Kalsi | ||
| Vol 2012, No 1 (2012) | BMS Adds Nucleotide Analogue to its HCV Pipeline with US$2.5 B Inhibitex Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2009, No 4 (2009) | BMS and Otsuka Extend Abilify Partnership | Abstract |
| Taskin Ahmed | ||
| Vol 2007, No 84 (2007) | BMS and Pfizer to collaborate on Thrombotic and Metabolic Disorders | Abstract pdf |
| Business Review Editor | ||
| Vol 2008, No 96 (2008) | BMS Bags a Bargain | Abstract pdf html |
| Sally Mardikian PhD | ||
| Vol 2015, No 3 (2015) | BMS Bets US$800 M Upfront That Flexus’ Preclinical IDO1 Inhibitor Is Best-in-Class | Abstract |
| Heather Cartwright | ||
| Vol 2015, No 11 (2015) | BMS Bolsters Cardiovascular Pipeline with Potential US$2.075 B Purchase of Cardioxyl | Abstract html |
| Heather Cartwright & Rohit Khera | ||
| Vol 2021, No 6 (2021) | BMS Bolsters Pipeline with Two Billion-Dollar Deals | Abstract pdf html |
| Michelle Liu | ||
| Vol 2014, No 5 (2014) | BMS Buys iPierian and its Anti-Tau Programme for a Potential US$725 M | Abstract |
| Heather Cartwright | ||
| Vol 2014, No 6 (2014) | BMS Continues Immuno-Oncology Push via Deals with CytomX and Incyte | Abstract |
| Heather Cartwright | ||
| Vol 2007, No 89 (2007) | BMS Enters the Biologics Acquisition Game | Abstract pdf |
| Business Review Editor | ||
| Vol 2016, No 1 (2016) | BMS Exits HIV R&D by Selling Pipeline to ViiV Healthcare | Abstract pdf html |
| Heather Cartwright & Sayani Datta | ||
| Vol 2017, No 4 (2017) | BMS Expands Collaboration with CytomX for US$200 M Upfront | Abstract pdf html |
| Natasha Piper | ||
| Vol 2014, No 4 (2014) | BMS Expands Immuno-Oncology Pipeline with Five Prime Partnership | Abstract |
| Heather Cartwright | ||
| Vol 2021, No 7 (2021) | BMS Expands Oncology Portfolio with Eisai’s MORAb-202 | Abstract pdf html |
| Neha Madhwani | ||
| Vol 2015, No 10 (2015) | BMS Fuels its Fibrotic Disease Pipeline with US$1.25 B Deal for Promedior | Abstract html |
| Heather Cartwright & Sayani Datta | ||
| Vol 2011, No 10 (2011) | BMS Gains Expanded Territorial Rights to Anti-PD-1 Antibody from Ono Pharmaceutical | Abstract |
| Heather Cartwright | ||
| Vol 2014, No 11 (2014) | BMS Gains Option to Acquire F-star Alpha and its HER2 Antibody Fragment in US$475 M Deal | Abstract |
| Heather Cartwright | ||
| Vol 2016, No 12 (2016) | BMS Harnesses Enterome’s Microbiome Technology in Immuno-Oncology | Abstract html pdf |
| Jasmine Kalsi | ||
| Vol 2018, No 2 (2018) | BMS Inks US$3.63 B Immuno-Oncology Collaboration with Nektar Therapeutics | Abstract html pdf |
| Arun Manohar | ||
| Vol 2019, No 1 (2019) | BMS Latest to Quit Consumer Health with UPSA Divestment | Abstract pdf html |
| Jawala Prasad & Michelle Liu | ||
| Vol 2011, No 7 (2011) | BMS Licenses Innate Pharma’s Phase I Immuno-Oncology Monoclonal Antibody | Abstract |
| Heather Cartwright | ||
| Vol 2017, No 11 (2017) | BMS Looks to Galvanise Opdivo’s Prospects with Halozyme’s Technology | Abstract html pdf |
| Jasmine Kalsi & Heather Cartwright | ||
| Vol 2005, No 60 (2005) | BMS Out-Licenses Two Early-Stage Drugs | Abstract |
| Business Review Editor | ||
| Vol 2020, No 6 (2020) | BMS Partners with Repare on Synthetic Lethal Target Discovery for US$65 M Upfront | Abstract pdf html |
| Michelle Liu | ||
| Vol 2016, No 4 (2016) | BMS seeks to invigorate its autoimmune pipeline with acquisition of Padlock | Abstract pdf html |
| Taskin Ahmed & Jasmine Kalsi | ||
| Vol 2011, No 8 (2011) | BMS Targets Fibrotic Disease with US$475 M Amira Pharmaceuticals Purchase | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 7 (2012) | BMS Teams Up with AstraZeneca to Buy Amylin for US$7 B | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 10 (2011) | BMS/Ambrx Deal Highlights Big Pharma’s Growing Interest in Protein Drug Engineering | Abstract |
| Heather Cartwright | ||
| Vol 2007, No 80 (2007) | Boehringer and Ablynx Sign US$265 M Deal for Use of Nanobodies® in Alzheimer’s Disease | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 88 (2007) | Boehringer and Ablynx to Partner Again | Abstract pdf |
| Business Review Editor | ||
| Vol 2009, No 5 (2009) | Boehringer and Exelixis to Collaborate in Autoimmune Diseases | Abstract |
| Taskin Ahmed | ||
| Vol 2012, No 7 (2012) | Boehringer Ingelheim Adds Phase II Anti-Inflammatory Drug to its Respiratory Disease Pipeline | Abstract |
| Heather Cartwright | ||
| Vol 2021, No 2 (2021) | Boehringer Ingelheim Buys ADC Specialist NBE-Therapeutics for US$1.43 B | Abstract pdf html |
| Ashish Tripathi & Michelle Liu | ||
| Vol 2020, No 1 (2020) | Boehringer Ingelheim Buys Rights to Enleofen’s Fibro-inflammatory Anti-IL-11 Platform | Abstract html pdf |
| Michelle Liu | ||
| Vol 2024, No 3 (2024) | Boehringer Ingelheim Collaborates with Sosei Heptares for Antipsychotic Drugs | Abstract pdf html |
| Amit Kaushik | ||
| Vol 2014, No 10 (2014) | Boehringer Ingelheim Enters Cancer Vaccine Field with CureVac Deal | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 6 (2011) | Boehringer Ingelheim Licenses Zealand Pharma’s Drug Candidates for Type 2 Diabetes and Obesity | Abstract |
| Heather Cartwright | ||
| Vol 2024, No 10 (2024) | Boehringer Ingelheim Signs Oncology Partnership with Circle Pharma for US$607 M | Abstract pdf html |
| Swati Sharan | ||
| Vol 2019, No 7 (2019) | Boehringer Ingelheim Strikes Third Deal of the Month with Bridge Biotherapeutics | Abstract pdf html |
| Michelle Liu | ||
| Vol 2019, No 10 (2019) | Boehringer Ingelheim Targets KRAS Mutations with Lupin’s LNP3794 | Abstract html pdf |
| Pratika Pahwa & Michelle Liu | ||
| Vol 2024, No 8 (2024) | Boehringer Ingelheim to Acquire Nerio Therapeutics for US$1.3 B | Abstract pdf html |
| Swati Sharan | ||
| Vol 2006, No 72 (2006) | Boehringer Ingelheim’s Bonanza Month | Abstract pdf |
| Business Review Editor | ||
| Vol 2008, No 97 (2008) | Boehringer Ingelheim’s Structured Venture into Biotech | Abstract pdf html |
| Sally Mardikian PhD | ||
| Vol 2003, No 39 (2003) | Boehringer Licenses Medivir’s MIV-310 Antiviral Drug | Abstract pdf |
| Business Review Editor | ||
| Vol 2021, No 3 (2021) | Boston Pharmaceuticals In-Licenses Another Two Programmes from GSK | Abstract pdf html |
| Michelle Liu | ||
| Vol 2019, No 5 (2019) | Boston Scientific Acquires Spinal Device Company Vertiflex | Abstract pdf html |
| Michelle Liu | ||
| Vol 2018, No 11 (2018) | Boston Scientific Continues M&A Spree with US$4.2 B BTG Deal | Abstract pdf html |
| Jawala Prasad & Michelle Liu | ||
| Vol 2006, No 78 (2006) | Bradely Pharmaceuticals Increases Portfolio via BioSante | Abstract pdf |
| Business Review Editor | ||
| Vol 2020, No 10 (2020) | Bristol Myers Squibb Acquires Cardiovascular Specialist MyoKardia for US$13.1 B | Abstract pdf html |
| Neha Madhwani & Michelle Liu | ||
| Vol 2024, No 1 (2024) | Bristol Myers Squibb Bolsters Pipeline with Two Multibillion-Dollar Acquisitions | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2022, No 6 (2022) | Bristol Myers Squibb Buys Turning Point for US$4.1 B | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2022, No 5 (2022) | Bristol Myers Squibb Licenses BridgeBio’s BBP-398 for Cancer | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2023, No 12 (2023) | Bristol Myers Squibb Signs Licensing Deal with Avidity Biosciences for Multiple Cardiovascular Targets | Abstract pdf html |
| Shweta Gupta | ||
| Vol 2022, No 10 (2022) | Bristol Myers Squibb Signs Protein Degradation and Cell Therapy Technology Deals | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2023, No 4 (2023) | Bristol Myers Squibb Signs US$1 B+ Deal with Tubulis for Solid Tumour ADCs | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2022, No 3 (2022) | Bristol Myers Squibb Signs US$1.1 B Metastatic Cancer Pact with Volastra | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2023, No 10 (2023) | Bristol Myers Squibb to Acquire Mirati Therapeutics for Up to US$5.8 B | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2009, No 7 (2009) | Bristol-Myers Squibb Acquires Medarex | Abstract |
| Taskin Ahmed | ||
| Vol 2003, No 41 (2003) | Bristol-Myers Squibb Acquires Rights to QDose’s Inhaled Insulin | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 82 (2007) | Bristol-Myers Squibb and Adnexus Therapeutics in Collaboration for Cancer Biologics | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 27 (2002) | Bristol-Myers Squibb and Exelixis Extend Two Research Collaborations | Abstract |
| Business Review Editor | ||
| Vol 2008, No 103 (2008) | Bristol-Myers Squibb and Exelixis Sign Cancer Deal | Abstract pdf html |
| Helen Scrutton | ||
| Vol 2008, No 99 (2008) | Bristol-Myers Squibb Deal Provides PDL with Much Needed Boost | Abstract pdf html |
| Helen Scrutton | ||
| Vol 2017, No 8 (2017) | Bristol-Myers Squibb Fights Immuno-oncology Competition with Early stage Biotech Acquisition | Abstract pdf html |
| Natasha Piper | ||
| Vol 2003, No 40 (2003) | Bristol-Myers Squibb Licenses Flamel’s Basulin® | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 38 (2003) | British Biotech and Vernalis Merger | Abstract |
| Business Review Editor | ||
| 701 - 800 of 2581 Items | << < 3 4 5 6 7 8 9 10 11 12 > >> | |